Unknown

Dataset Information

0

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.


ABSTRACT: The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing. The Working Group considered the functional impact of the variants, allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx genes and alleles across clinical laboratories. These recommendations are not to be interpreted as restrictive but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity-associated genes and alleles.

SUBMITTER: Pratt VM 

PROVIDER: S-EPMC7057225 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Pratt Victoria M VM   Cavallari Larisa H LH   Del Tredici Andria L AL   Hachad Houda H   Ji Yuan Y   Moyer Ann M AM   Scott Stuart A SA   Whirl-Carrillo Michelle M   Weck Karen E KE  

The Journal of molecular diagnostics : JMD 20190508 5


The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laborator  ...[more]

Similar Datasets

| S-EPMC7722527 | biostudies-literature
| S-EPMC5496684 | biostudies-literature
| S-EPMC6941185 | biostudies-literature
| S-EPMC5707196 | biostudies-literature
| S-EPMC7240346 | biostudies-literature
| S-EPMC2881855 | biostudies-literature
| S-EPMC5971222 | biostudies-literature
| S-EPMC4086638 | biostudies-literature
| S-EPMC4544753 | biostudies-literature
| S-EPMC4346183 | biostudies-literature